Tulane University, Health Sciences Center, Department of Urology, 1430 Tulane Avenue, SL-42, New Orleans, LA 70112, USA.
Expert Opin Investig Drugs. 2010 Nov;19(11):1427-37. doi: 10.1517/13543784.2010.518955. Epub 2010 Oct 13.
Erectile dysfunction (ED) is a common sexual problem, affecting up to half of men over 50 years of age. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil and vardenafil) are currently the first-line treatment option presented to patients with ED. There exists a significant number of men who remain dissatisfied with the available therapies and are either unable to achieve their therapeutic goals or unwilling to tolerate adverse side effects. Therefore, development of novel PDE5 inhibitors with enhanced selectivity, faster onset of action, increased potency and improved tolerability is desirable.
Preclinical and clinical studies of avanafil, a new oral PDE5 inhibitor being investigated for the treatment of ED. Data were obtained by searching for all English peer-reviewed articles on Medline and any related abstracts presented on avanafil at major international congresses.
An understanding of the pharmacokinetic and pharmacodynamic characteristics of avanafil and insight into the drug's clinical efficacy and safety profile.
We propose that avanafil, which displays enhanced selectivity, faster onset of action, and a favorable side-effect profile relative to currently available PDE5 inhibitors, may offer an alternative first line treatment option for men with ED.
勃起功能障碍（ED）是一种常见的性问题，影响多达一半的 50 岁以上男性。磷酸二酯酶 5（PDE5）抑制剂（西地那非、他达拉非和伐地那非）是目前向 ED 患者推荐的一线治疗选择。有相当数量的男性对现有治疗方法不满意，要么无法达到治疗目标，要么不愿意忍受不良反应。因此，开发具有更高选择性、更快起效、更强效力和更好耐受性的新型 PDE5 抑制剂是理想的。
正在研究用于治疗 ED 的新型口服 PDE5 抑制剂阿伐那非的临床前和临床研究。通过在 Medline 上搜索所有英文同行评议文章，并在主要国际大会上搜索关于阿伐那非的任何相关摘要，获得了数据。
了解阿伐那非的药代动力学和药效学特征，并深入了解该药物的临床疗效和安全性概况。
我们提出，与目前可用的 PDE5 抑制剂相比，阿伐那非具有更高的选择性、更快的起效时间和更有利的副作用谱，可能为 ED 男性提供一种替代的一线治疗选择。
